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Abstract
Background: Assessing drug users’ attitudes towards different kinds of addiction treatment is necessary to design
tailored strategies. The aim of the present study is to develop and examine the psychometric properties of a new
scale, called the DUAMMT, for assessing drug users’ attitudes toward methadone maintenance treatment in Iran.
Methods: A multi-phase development method was applied in developing an instrument from February to
December 2016. The item generation and scale development were performed through literature review, a
qualitative approach, and interviews with an expert panel. Then, the psychometric properties of the scale were
evaluated by means of cross-sectional studies with drug users. We performed an exploratory factor analysis, a
confirmatory factor analysis, and item-scale correlations; and we tested the internal consistency of the scale.
Furthermore, test-retest reliability was evaluated among an Iranian sample of drug users.
Results: The mean age of participants was 34.12 years. The exploratory factor analysis revealed four factors
(perceived barriers, perceived concerns, methadone side effects, and perceived positive effects) containing 17 items
that jointly accounted for 60.53% of the observed variance. The confirmatory factor analysis showed a model with
appropriate fitness for the data. The Cronbach’s alpha coefficient for the subscales ranged from .70 to .79. The
intra-class correlation coefficient (ICC) ranged from .774 to .970, which is well above the acceptable threshold.
Conclusions: The findings of the present study suggest that the DUAMMT is a valid and reliable instrument to
measure drug users’ attitudes toward methadone maintenance treatment. The DUAMMT can be applied at the start
of treatment so that clinical intervention can be targeted to promote retention in treatment.
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Background
The International Classification of Diseases (ICD-10) has
classified opioid dependence as a chronic and relapsing
disorder [1]. Opioid use disorder has been a main contribu-
tor to comorbidity and premature mortality caused by
overdose and blood-borne infections, such as human
immunodeficiency virus (HIV) and hepatitis [2–6]. In
addition, opioid dependence was responsible for 51,000
deaths throughout the world in 2013 [7] and also
accounted for the greatest proportion of universal
disability-adjusted life years (DALYs) attributed to drug
dependence, i.e., 9.2 million DALYs in 2010 [8]. More
concerns may be raised considering the fact that DALYs
attributed to opioid use disorder increased during the time
period of 1990–2010 [8]. Aside from physical harm, previ-
ous studies have also shown that people with opioid use
disorders have higher risks of panic disorders, social phobia,
agoraphobia, low self-reported health, lifetime anxiety, and
mood disorders [2, 9, 10].
Methadone, which is a synthetic opioid with potent
analgesic effects, was initiated in Germany during World
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War II and was prescribed as a painkiller. In 1964, however,
the first “methadone program” was established by Dole and
Nyswalder (1965) in order to treat heroin dependence [11,
12]. Methadone maintenance treatment (MMT) is an opioid
replacement therapy (ORT); taking stable daily doses of
methadone in the long term has been proven to alleviate the
uncomfortable withdrawal symptoms of opioid abstinence,
reduce opioid craving, and block opioid euphoria [6, 11, 12].
Although opioid replacement therapies have not been lim-
ited to methadone maintenance treatments in contemporary
decades, MMT has been widely accepted as one of the best
evidence-based medication-assisted therapies for chronic
opioid dependence and can be considered a harm reduction
strategy [6, 12–14]. Methadone has a positive influence on
public health and security as well as human capital and
social productivity [15–17]. There is evidence that in low-
and middle-income countries where there is a lack of treat-
ment programs, the expansion of MMT programs might
lead to savings in social and health expenditures [5, 13, 18].
Meta-analysis of different data found that MMT is highly
efficient in reducing heroin dependence [19], reducing risky
behavior related to HIV transmission [20], reducing
overdose-related deaths [21], and reducing crime rate [22].
Although MMT programs are one of the most important
treatment strategies to reduce individual and public harm
associated with opioid use, and despite the central role of
methadone therapy in harm reduction approaches to opioid
use in Iran as well as many other countries, previous stud-
ies have pointed out that a large proportion of eligible pa-
tients refuse to participate in this treatment program [4, 16,
23–25]. There are some factors that prevent the tendency
of patients to use this treatment, such as lack of access and
high cost. Evidence has shown that some other items, such
as attitudes and beliefs of patients regarding methadone
treatment, can affect their acceptance of this treatment
[26]. Positive attitudes toward methadone treatment have
been related to retention in treatment [27].
Thus, assessing drug users’ attitudes toward different
kinds of addiction treatment may be necessary to design
more effective treatment plans. High prevalence of illicit
drug use [28]; being close to major illicit drug production
regions in Afghanistan [29]; social, cultural, and economic
special conditions [30]; and huge problems regarding drug
treatment [31] are all reasons the development of instru-
ments related to addiction treatment in Iran has priority. A
United Nations Office on Drug and Crimes (UNODC)
report indicated that more than 80% of the recognized
drug treatment seekers in Iran were primarily people with
opioid use disorders [32]. Although many Iranian
researchers have attempted to develop instruments for
addiction treatment [33–36], none of them focused on
respondents’ attitudes toward methadone. Thus, the aim of
the present study is to develop and examine the psycho-
metric properties of a new scale, called the DUAMMT, for
assessing Iranian drug users’ attitudes toward methadone
maintenance treatment.
Methods
Research design
This study was approved by the Ethics Committee of Kur-
distan University of Medical Sciences [Grant number 14/
23311], and all patients completed informed written con-
sent. The study was conducted in two phases. Firstly, item
generation and scale development were performed by ap-
plying three approaches: a literature review, a qualitative
method approach, and interviews with an expert panel. In
the second phase, the psychometric properties of the scale
were evaluated by means of cross-sectional studies with
drug users. We performed exploratory factor analysis, con-
firmatory factor analysis, and item-scale correlation, and we
assessed the internal consistency of the scale. Furthermore,
test-retest reliability was evaluated among an independent
sample of 30 drug users. Table 1 provides the descriptive
characteristics of the participants from the two phases.
Phase 1: Item generation and scale development phase
In this phase, we aimed to develop an instrument to meas-
ure drug users’ attitudes toward MMT. Two methods
were applied to develop an item pool in the present study:
First, a qualitative study was designed to explore the
drug users’ attitudes toward MMT. For the purpose of this
phase, 12 individual interviews were conducted among a
sample of drug users. Patients were recruited from drop-
in centers (DICs) and MMT centers in Sanandaj, Iran.
The DICs are run by local nongovernmental organizations
offering therapies and psychosocial support and facilitat-
ing self-help groups. Maximum variation sampling was
used in this phase, meaning that we recruited participants
with different sociodemographic characteristics so that
they complement each other’s viewpoints in experiencing
methadone. In order to obtain maximum variation, pa-
tients engaging in various types of drug use were chosen
from different ages and socioeconomic backgrounds. The
descriptive characteristics of patients are shown in Table 1.
In-depth individual interviews delivered a condition for us
to talk about patients’ beliefs about methadone treatment
and, as a result, to recognize the level of their attitudes.
Patients had different levels of education.
The interviews were initiated by defining maintenance
treatment and applying a semi-structured inventory that
started with an open-ended question: “What is your opinion
about methadone treatment?” Then, based on the answers
from the patients, several questions were asked to promote
discussion. All discussions were recorded, and we wrote our
analytic concepts in a memo text.
All patients were informed about the aim of the study,
and they filled in the informed consent. The interviews
were held in the DIC and MMTcenters, and all discussions
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were tape-recorded. Data saturation was achieved after 12
individual interviews. Afterward, we applied an inductive
method to analyze the recorded discussions. Inductive con-
tent analysis was applied to detect themes by studying the
raw data of the interviews through continuous comparison
[37]. Clear procedures were used to draw conclusions from
the interviews in order to ensure credibility. For transfer-
ability, we provided rich explanations that can be applied
by other researchers to other situations and backgrounds.
Furthermore, in order to ensure conformability, we
checked the internal coherence of the results [38].
Thereafter, experts were asked, “What are the most effect-
ive treatments for addiction and relapse prevention in people
with opioid use disorders? Why do you consider these im-
portant? And why do you think the other treatments for drug
users are not as important as your selected approaches?”
In the end, all data obtained from qualitative research and
interviews with experts were cross-checked, and based on
the three approaches, 30 items in Farsi were created for an
initial scale. Each item was rated on a 5-point Likert scale
ranging from 1 (strongly agree) to 5 (strongly disagree).
Subsequently, content and face validity were evaluated.
Content validity
In this study, both qualitative and quantitative content
validity (content validity index/ratio) were assessed. In the
qualitative stage, a scientific panel of 10 experts (including
health educators, psychologists, and addiction therapists)
evaluated the initial scale. They evaluated the grammar,
wording, and scaling of each item. To assess the quantita-
tive content validity, both the content validity index (CVI)
and content validity ratio (CVR) were calculated. The sim-
plicity, accuracy, and clarity of each item were measured by
the CVI [39, 40]. In order to calculate the CVI, a 4-point
Likert-type ordinal scale was applied by the expert panel.
The answers were rated between 1 (not relevant, not clear,
and not simple) and 4 (very relevant, very clear, and very
simple). The CVI was assessed as the proportion of items
that received a rating of 3 or 4 by the experts [41]. A CVI
score lower than .80 was not acceptable [42]. The essential-
ity of the items was tested by the CVR. Each item was
scored by the expert panel as 1 (essential), 2 (useful but not
essential), or 3 (not essential) [41]. Then, based on the
Lawshe Table [43], items with a CVR score of 0.62 or above
were considered to be acceptable and were retained.
In the quantitative stage, items with a CVR and CVI
less than .62 and .82, respectively, were deleted.
In total, 8 items were deleted, resulting in a 22-item pool.
Furthermore, the expert panel revised the scale with regard
to grammar, wording, and item allocation. For example, the
sentence “Methadone treatment does not reduce return to
reusing drug” was changed to “Methadone does not have
an effect on the prevention of relapse.” The 22-item pool
remained in the analyses below and consisted of positively
worded and negatively worded statements with five re-
sponse options: 1 = totally disagree, 2 = disagree, 3 = neither
disagree nor agree, 4 = agree, and 5 = totally agree.
Face validity
In this step, both qualitative and quantitative approaches
were used to assess face validity. A group of drug users (n
= 10) were asked to evaluate each item of the scale and to
indicate if they felt ambiguity or difficulty in answering the
Iranian version of the DUAMMT questionnaire. Based on
the respondents’ perspectives, the ambiguous items were
adapted. In the quantitative phase, the impact score
(frequency × importance) was assessed to show the
percentage of drug users who identified each item as im-
portant or somewhat important on a 5-point Likert scale.
Items were considered to be inappropriate if they had an
Table 1 Characteristics of the study sample
EFA sample (n = 200) CFA sample (n = 120) Test-retest sample (n = 30)
Age (years)
Mean 34.12 ± 8.57 36.12 ± 9.43 27.11 ± 6.11
Range 21–70 18–75 22–48
Employment status
(n / %) Unemployed 44 (22%) 42 (21%) 11 (36%)
Employed full time 156 (78%) 78 (39%) 19 (63%)
Educational level
(n / %) Primary 67 (33%) 53 (44.1%) 7 (23%)
Secondary 101 (50%) 42 (35%) 15 (50%)
Higher 32 (16%) 26 (21.6%) 8 (26%)
Marital status
(n / %) Single/divorced/widowed 87 (43%) 43 (35.8%) 13 (43.3%)
Married 113 (56.5%) 77 (64.1%) 17 (56.6%)
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impact score less than 1.5 (which matches a mean
frequency of 50% and a mean importance of three on the
5-point Likert scale) [44]. Overall, three items had an im-
pact score less than 1.5 and were deleted. The range of the
impact score for the remaining 19 items was from 1.7 to 5.
The first form of the questionnaire containing 19 items was
established for the next phase of psychometric evaluation.
Phase 2: Psychometric phase
The main study and the data collection
In order to assess the psychometric properties of the
DUAMMT questionnaire in a wider setting, a cross-sectional
study was designed to be carried out in Sanandaj, Iran, from
February to December 2016. A simple random sampling
method was applied. Firstly, four DIC and MMTcenters were
randomly selected among DIC and MMT centers in Sanan-
daj, Iran. patients who visited DIC and MMT centers were
entered into the study if they were male patients with sub-
stance abuse referred to harm reduction centers, met the
diagnostic criteria for substance dependence disorder based
on the DSM-IV, were literate, and wanted to take part in the
study. After the main investigator provided an explanation
about the aim of the study, patients who agreed to take part
in this study completed the DUAMMT questionnaire. In
addition, the demographic characteristics of patients including
age, educational level, employment status, marital status, and
type of drug use were also collected. In order to collect data,
educated investigators conducted face-to-face interviews.
Statistical analysis
Several statistical methods were applied to test the psy-
chometric properties of the DUAMMT scale. These are
presented as follows.
Validity
Construct validity
After the item analysis, the 19 remaining items were
considered to estimate the construct validity using ex-
ploratory factor analysis (EFA), confirmatory factor ana-
lysis (CFA), and item-scale correlation.
Exploratory factor analysis EFA was performed to
identify the main factors of the scale. The sample size was
estimated a priori. As recommended by Gable and Wolf, a
sample of five to ten patients per item is required to ensure
a conceptually clear factor structure for EFA [45]. The
preferred maximum required sample size was thus deter-
mined to be 200 drug users. These patients were recruited
from the DIC and MMT centers. The main factors of the
scale were extracted by performing EFA, applying the
principal component analysis (PCA) with varimax rotation.
The Kaiser-Meyer-Olkin (KMO) test and Bartlett’s test of
sphericity were applied to assess the adequacy of the sam-
ple for the factor analysis [46]. In order to extract the
factors, a factor with an eigenvalue above 1 was considered
significant. Additionally, a scree plot was used to specify
the number of factors. Factor loadings equal to or greater
than .40 were considered acceptable [47].
Confirmatory factor analysis (CFA) A CFA was per-
formed in order to assess the fit of the model. Considering
the possible attrition related to test-retest analysis, a separate
sample of 120 drug users was planned to be recruited from
harm reduction, MMT, and DIC centers. Assigning seven
patients to each item, a sample size of 120 was estimated
[48]. The model fit was evaluated using multiple fit indices.
As suggested, several fit indices measuring relative chi-
square (χ2/df), comparative fit index (CFI), goodness of fit
index (GFI), non-normed fit index (NNFI), normed fit index
(NFI), root mean square error of approximation (RMSEA),
and standardized root mean square residual (SRMR) were
taken into account [49, 50]. Relative chi-square is the chi-
square ratio to degrees-of-freedom, and it is suggested that a
value less than 3 indicates an acceptable fit [51]. The values
of GFI, CFI, NNFI, and NF range from 0 to 1, but values
equal to 0.90 or above are commonly indicated as acceptable
model fits [52]. An RMSEA value between .08 and .10 indi-
cates an average fit, and a value below .08 shows a good fit.
Values below .05 indicate a good fit for SRMR, but values be-
tween .05 and .08, and between .08 and .10, indicate a close
fit or are acceptable, respectively [53].
Item-scale correlation Finally, item-scale correlations
were calculated in order to assess the degree to which each
item was correlated to its subscale by use of the Spearman
correlation coefficient. We expected that, for each subscale
of the DUAMMT, the item scores of the subscale (e.g., per-
ceived barriers) would correlate more with the total score of
the respective subscale (e.g., perceived barriers) rather than
the total score of other subscales (e.g., perceived side effects).
Correlation values between 0 and .20 are considered poor;
between .21 and .40, fair; between .41 and .60, good; between
.61 and .80, very good; and above .81, excellent [54].
Reliability
Internal consistency The internal consistency of the
DUAMMT questionnaire was assessed by calculating the
Cronbach’s’ alpha coefficient of the whole scale and each
dimension of the DUAMMT questionnaire. Alpha values
equal to .70 or higher were considered acceptable [54, 55].
Test-retest A subsample of drug users (n = 30) filled out
the DUAMMT questionnaire twice, with a 2-week interval,
in order to examine the stability of the questionnaire by es-
timating the intra-class correlation coefficient (ICC). ICC
values of .40 or above are considered acceptable [55]. All
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statistical analyses, except CFA, were performed using SPSS
18.0 [56]. The CFA was performed using LISREL 8.80 [57].
DUAMMT questionnaire The final version of the
DUAMMT questionnaire is shown in Appendix 1. Each
item is rated on a five-point response scale. Four items were
negatively worded (items 2, 11, 13, and 15) and have to be
reverse scored [Appendix 2].
Results
Construct validity
Exploratory factor analysis
The measured KMO was .742, and the Bartlett’s test of
sphericity was significant (χ2 = 644.03, p < .001), indicating
adequacy of the sample for EFA. Initially, for the 19-item
scale, seven factors showed eigenvalues above 1.0, explaining
the 60.53% variance. Additionally, the scree plot showed a
4-factor solution (Fig. 1). This 4-factor solution was explored
by repeatedly assessing the item performance by eliminating
the items in a step-by-step process. After removing the
items with factor loadings below .40, a final factor solution
was obtained that consisted of a 17-item questionnaire load-
ing on four distinct constructs. These constructs jointly
accounted for 60.53% of the observed variance.
As presented in Table 2, four factors were found: Factor 1
(perceived barriers toward methadone treatment) included
7 items (items 11, 12, 13, 14, 15, 16, and 17), factor 2 (per-
ceived side effects) included 4 items (items 1, 2, 3, and 4),
factor 3 (perceived concerns) included 3 items (items 5, 6,
and 7), and factor 4 (perceived positive effects) included 3
items (items 8, 9, and 10). Refer to Appendix 1 for the
items of the DUAMMT.
Confirmatory factor analysis
CFA on the 17-item DUAMMT questionnaire was con-
ducted to test the fitness of the model obtained from the
EFA. Figure 2 shows the best model fit for the DUAMMT
questionnaire. Covariance matrices were used, and fit indi-
ces were calculated. All fit indices proved to be acceptable.
The relative chi-square (χ2/df) was equal to 2.04 (p < .001).
The RMSEA of the model was .039 (90% CI = .001–.063),
and the SRMR was .030. All comparative indices of the
model, including GFI, AGFI, CFI, NNFI, and NFI, were
more than .80 (.88, .84, .92, .90, and .80, respectively).
Item-scale correlation
Table 3 presents the item-scale correlation for the
DUAMMT questionnaire. As can be seen, all coefficients
are higher than .20, and most of them are higher than 0.40.
Perceived barriers and perceived positive effects had the
lowest and the highest item-scale correlation, respectively.
Reliability
In order to measure the reliability, the Cronbach’s alpha
was calculated separately for the DUAMMT and each fac-
tor of the DUAMMT. The Cronbach’s alpha coefficient for
Fig. 1 Scree plot for determining factors of the designed instrument
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the DUAMMT was .93 and ranged from .70 to .79 for its
subscales, which is well above the acceptable threshold.
Therefore, no items of the scale were omitted in this phase.
In addition, test-retest analysis was conducted to test the
stability of the DUAMMT questionnaire. The results indi-
cated satisfactory results. ICC was .94 (good to excellent)
for the DUAMMT and ranged from .774 to .970 for the
subscales of the DUAMMT, lending support for the stabil-
ity of the scale. The results are presented in Table 4.
Discussion
Because there is not a questionnaire to measure attitudes to-
ward methadone in Iran, the present study as initial research
described the development and psychometric properties of
the questionnaire for assessing the attitudes toward metha-
done maintenance treatment in Iran. The results demon-
strated that the final 17-item DUAMMT questionnaire is a
robust, valid, and reliable questionnaire that comprises four
subscales (perceived barriers, perceived concerns, methadone
side effects, and perceived positive effects).
Overall literature review showed similar studies developing
scales for assessing attitudes toward methadone. For in-
stance, the 36-item Brown questionnaire that assesses atti-
tude toward methadone contains two factors (barriers and
benefits of methadone) [58]. Similarly, Kayman et al. devel-
oped a 14-item questionnaire to measure beliefs about
methadone that contained four constructs: benefits of MMT,
treatment-related barriers, reduction of crime, and feelings
about leaving the methadone program [59]. In addition,
Caplehorn developed a 53-item questionnaire to measure at-
titudes toward addiction and methadone, which included
knowledge about methadone maintenance, disapproval of
drug use, abstinent-orientation, attitude toward methadone,
and attitude toward illegal drugs. In Caplehorn’s study, atti-
tudes about methadone were not specifically investigated in
their questionnaire; they only considered attitudes about il-
legal drugs [60]. Also, Schwartz and colleagues assessed atti-
tudes toward methadone by using the attitudes toward
methadone scale that contains 28 items related to percep-
tions of methadone potential helpfulness, negative physical
and cognitive effects associated with methadone, and the
perceived purpose of methadone treatment.
It is noteworthy that so far, none of these tools have
been translated or used in any research in Iran. Other
similar tools are more focused on barriers and perceived
benefits, but in the DUAMMT, perceived barriers are
explained in detail, and methadone side effects have
been investigated in detail. Most of the participants in
the qualitative study indicated methadone side effects.
The items of the DUAMMT were developed using a quali-
tative study. Thereafter, we conducted both exploratory and
factor analyses; the results showed that the structure of the
questionnaire was good. EFA showed that the total variance
of the questionnaire was 60%, and the CFA indicated that
the factor structure of the questionnaire was suitable. In this
study, the χ2/df ratio was 1.43, the GFI for the model was
Table 2 Exploratory factor analysis of the DUAMMT (n = 200)
Factor 1 Factor 2 Factor 3 Factor 4
Q12. Methadone treatment is long term. .762 .079 .075 −.190
Q16. I do not receive adequate counseling at the Methadone Therapy Center. .699 .042 .253 .010
Q13. Methadone does not have an effect on the prevention of relapse. .690 −.133 .139 −.209
Q15. Methadone treatment centers are not available enough. .633 .023 .421 .110
Q14. Daily clinic visits for methadone are hard for me. .507 .115 .056 .383
Q17. Methadone treatment is costly. .424 .081 .261 .400
Q11. Methadone does not help addiction treatment. .406 .324 −.096 .326
Q18. Methadone reduces contact with drug dealers .281 .225 .210 .338
Q19. Methadone reduces clashes with the police. .344 −.241 .236 305
Q1. Methadone is addictive. .107 .669 −.125 −.069
Q3. Methadone decreases my sexual activity. .060 .608 .078 .023
Q2. Methadone makes me sleepy. −.196 .475 .169 .096
Q4. Methadone has negative effects on my health (constipation, liver problems, heart pain). −.018 .459 .001 −.065
Q6. Daily clinic visits for methadone have a negative effect on my family relationships. .241 −.140 .695 .086
Q7. I’m scared to see one of my relatives in a methadone treatment center. .202 −.038 .677 .173
Q5. Daily clinic visits for methadone threaten my family life and my job. −.109 .331 .520 −.248
Q10. Methadone makes me feel euphoric. −.102 .082 .173 .616
Q8. Methadone reduces the temptation to consume drugs. .153 .312 .030 .529
Q9. I’ve had more clean days with methadone. −.065 .352 .293 .523
Note. Figures in bold represent factor loadings equal to or above .40
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0.001, the SRMR was 0.80, and the NNFI was 0.92. These re-
sults indicate that the model was a very good fit for our data.
According to EFA, four latent factors were extracted.
These subscales were named by considering the con-
cepts and after several meetings with expert panel mem-
bers. In the present study, we also applied CFA, which is
superior compared to analyses of other studies, such as
those used in the study by Kayman and colleagues [59]
or Brown and colleagues [58].
The internal consistency of the final instrument as
assessed by the Cronbach’s alpha and the test-retest co-
efficient was found to be .70 and .93, respectively, indi-
cating acceptable reliability and homogeneity of the
items of the DUAMMT. Compared to the Brown ques-
tionnaire, the Cronbach’s alpha of the DUAMMT was
higher at 0.89 vs 0.68. The Caplehorn scale calculated
only the overall Cronbach’s alpha, with a value of
0.89 [60]. The reliability of the present questionnaire
was also higher than that of the Kayman et al. [59]
questionnaire (0.60), indicating the fundamental reli-
ability of this tool among the patients struggling with
drug abuse.
The DUAMMT is able to identify attitudes toward
methadone as well as predict retention among patients.
Kayman and colleagues, utilizing an abbreviated version of
the methadone scale, found that attitudes toward metha-
done predict retention in methadone treatment [59].
Based on the results, the validity proved to be good, as
well as the reliability and stability of the questionnaire.
There is a lack of appropriate tools to measure attitudes
toward methadone in Iran. This questionnaire can be used
as a standard questionnaire in future studies.
The present study, however, has some limitations. First,
with regard to the sampling, we only interviewed drug users
who were treated in MMT centers in Sanandaj. Because
these patients are culturally homogeneous, their viewpoints
may not be generalized to the views of patients treated in
other cultures. Consequently, it might be interesting for fu-
ture studies to test the reliability and validity of the
DUAMMT in a sample of drug users from different cultural
backgrounds and areas. Second, regarding the sampling, 22%
of the patients in the present study were unemployed and
100% were men. In future studies, it would be necessary to
examine the psychometric properties of the DUAMMT in
Fig. 2 A four-factor model for the questionnaire obtained through confirmatory factor analysis (n = 120)
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patients from both urban and rural areas with different levels
of education, employment status, and economic status.
Third, the DUAMMT was developed by only using samples
of men, and was tested among men, as a result, it may not
be representative of women with opioid use disorders. Future
studies should examine its validity and reliability among
women as well. Furthermore, in this study, we did not test
how the DUAMMT is associated with similar scales. How-
ever, one of the strengths of the study is that two separate
samples were recruited for the EFA and CFA. Attitude
toward methadone treatment is related to retention in
treatment. Also, long-term retention in treatment has a
favorable outcome for both patients and society.
Conclusions
Generally, the findings of the present study suggest that the
DUAMMT is a valid and reliable instrument to measure the
attitudes towards MMT among male opioid users in Iran.
Further studies in different populations, and particularly with
women, are recommended to establish stronger psychomet-
ric properties for the questionnaire. Such studies can enhance
the tailoring of appropriate MMT to optimize successful out-
comes among people with opioid use disorders.
Appendix 1
PSE: Perceived side effects.
Q1. Methadone is addictive.
Q2. Methadone makes me sleepy.
Q3. Methadone decreases my sexual activity.
Q4. Methadone has negative effects on my health
(constipation, liver problems, heart pain).
PC: Perceived concerns.
Q5. Daily clinic visits for methadone threaten my fam-
ily life and my job.
Q6. Daily clinic visits for methadone have a negative
effect on my family relationships.
Q7. I’m scared to see one of my relatives in a metha-
done treatment center.
PPE: Perceived positive effects.
Q8. Methadone reduces the temptation to consume
drugs.
Q9. I’ve had more clean days with methadone.
Q10. Methadone makes me feel euphoric.
PB: Perceived barriers.
Q11. Methadone does not help addiction treatment.
Q12. Methadone treatment is long term.
Q13. Methadone does not have an effect on the pre-
vention of relapse.
Q14. Daily clinic visits for methadone are hard for me.
Q15. Methadone treatment centers are not available
enough.
Q16. I do not receive adequate counseling at the
Methadone Therapy Center.
Q17. Methadone treatment is costly.
Appendix 2.
Q2. Methadone makes me sleepy.
Q11. Methadone does not help addiction treatment.
Q13. Methadone does not have an effect on the pre-
vention of relapse.
Q15. Methadone treatment centers are not available
enough.
Table 3 Item-scale correlation matrix for the four DUAMMT
constructs (n = 200)
DUAMMT Dimensions
PB PSE PC PPE
PB (item number)
Item 11 .340 .049 .015 −.018
Item 12 .419 −.036 .127 .120
Item 13 .440 −.012 −.102 .205
Item 14 .628 −.016 .075 .071
Item 15 .781 .040 .218 .044
Item 16 .754 −.048 .248 .038
Item 17 222 −.029 .078 −.087
MSE (item number)
Item 1 −.027 .631 −.102 .251
Item 2 −.016 .603 −.104 .266
Item 3 −.083 .604 .001 .094
Item 4 .085 .621 −.086 .206
PC (item number)
Item 5 −.160 .069 .642 .113
I tem 6 .364 −.183 .708 −.189
Item 7 .246 −.179 .703 .057
PPE (item number)
Item 8 .083 .303 −.025 .829
Item 9 .004 .243 .046 .767
Item 10 .094 −.056 −.013 .089
Note1. PB Perceived barriers, PSE Perceived side effects, PC Perceived concerns,
PPE Perceived positive effects
Note2. The bold and italicize data reflect higher correlations for the four
DUAMMT dimensions. All coefficients are higher than .20
Table 4 Measures of internal consistency and stability
Factor Name Number of items Cronbach’s
alpha (n = 200)
ICC
(n = 30)
1 Perceived barriers 7 items (11–17) .788 .844
2 Perceived side
effects
4 items (1–4) .710 .774
3 Perceived concerns 3 items (5–7) .704 .784
4 Perceived positive
effects
3 items (8–10) .725 .970
Total 17 items .932 .938
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